Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 11/20 | 0.41 |
| ▸ | BCHE | P06276 | 8/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 3/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2789343 | 0.90 | LTA4H (0.48) | ACHEBCHEHDAC3HDAC1HDAC2 | |
| SCHEMBL2790125 | 0.88 | ACHE (0.43) | ACHEBCHELTA4H | |
| SCHEMBL12991254 | 0.83 | ACHE (0.39) | ACHEBCHELTA4H | |
| SCHEMBL12972897 | 0.83 | FDPS (0.56) | — | |
| SCHEMBL2788674 | 0.80 | LTA4H (0.49) | ACHEBCHELTA4H | |
| SCHEMBL17166935 | 0.79 | HDAC6 (0.41) | HDAC3HDAC1HDAC2HDAC6NCOR2 | |
| SCHEMBL17156982 | 0.76 | LTA4H (0.54) | ACHEBCHELTA4H | |
| SCHEMBL2786701 | 0.75 | LTA4H (0.50) | ACHEBCHELTA4H | |
| SCHEMBL17166936 | 0.75 | GGPS1 (0.38) | ACHEBCHEHDAC3HDAC1HDAC2 | |
| SCHEMBL2787271 | 0.74 | LTA4H (0.45) | ACHEBCHELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240501-B1 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR FOR TARGETING BONE TISSUE | UNIV NANTES (FR) | 2015-10-14 | — | — | EP | disclosed |
| US-8361993-B2 | Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue | UNIVERSITE DE NANTES (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8361993-B2 | Hydroxy-bisphosphonic acid derivatives as vector targeting bone tissue | UNIVERSITE DE NANTES (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20100311695-A1 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR TARGETING BONE TISSUE | UNIVERSITE DE NANTES | 2010-12-09 | — | — | US | disclosed |
| US-20100311695-A1 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR TARGETING BONE TISSUE | UNIVERSITE DE NANTES | 2010-12-09 | — | — | US | disclosed |
| WO-2009083614-A1 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR FOR TARGETING BONE TISSUE | UNIVERSITE DE NANTES (FR) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311695-A1 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR TARGETING BONE TISSUE | BPGM, SOST, PTH1R | ACHE 4870/4885BCHE 3344/4885HDAC3 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.